Multiple Myeloma Market, Size, Global Forecast 2023-2030, Industry Trends, Growth, Share, Outlook, Impact of Inflation, Opportunity Company Analysis
Global Multiple Myeloma Market Outlook
Multiple Myeloma Market will reach US$ 16.31 Billion in 2030 compared to 10.20 Billion in 2022, according to Renub Research. Multiple myeloma, or Kahler's disease, is a cancer that impacts plasma cells, white blood cells that generate antibodies to combat infections. The condition results in an accumulation of abnormal plasma cells in the bone marrow, which produce an abnormal protein called monoclonal immunoglobulin (M protein) that may damage the bones and other organs.
According to the Globocan, there were an estimated 19,292,789 new cancer cases, resulting in approximately 9,958,133 cancer-related deaths. In addition, the International Agency for Research on Cancer (IARC) projects that the global cancer incidence will rise to 27.5 million new cases with 16.3 million deaths by 2040.
Multiple Myeloma markets shall experience a CAGR of 6.04% from 2022 to 2030
Multiple myeloma, the second most prevalent type of blood cancer after non-Hodgkin lymphoma, is identified by the uncontrolled growth of abnormal plasma cells within the bone marrow. The malignant plasma cells displace normal blood cells, causing low blood counts, bone deterioration, and possible kidney impairment. Recent advancements in drugs for multiple myeloma have revolutionized treatment in the last decade, and future agents in development offer promising breakthroughs.
An increase in early detection and diagnosis of multiple myeloma leads to earlier treatment and better patient outcomes. Moreover, advancing targeted therapies and immunotherapies have led to the development of newer and more effective treatments for multiple myeloma. Finally, increased awareness and advocacy efforts for multiple myeloma may lead to more research funding and greater attention to the condition, further driving growth in the industry.
Chemotherapy will be the most preferred type of Treatment in the Future
Targeted Therapy, Chemotherapy, and Others are the different treatment types used in the multiple myeloma industry. Chemotherapy is a critical component of multiple myeloma treatment and has contributed to the growth of the chemotherapy market in this field. It effectively kills dividing cancer cells, vital for controlling abnormal plasma cell proliferation. New chemotherapy drugs with improved efficacy and reduced toxicity have increased their use in treating multiple myeloma. Moreover, chemotherapy is often combined with other treatments, such as immunotherapy and targeted therapy, to improve outcomes. Therefore, the demand for chemotherapy treatments will grow as multiple myeloma prevalence increases.
Males are at a greater risk of developing the Disease
Both Male and Female genders are at risk of multiple myeloma. Males have higher levels of androgens that can promote the growth of abnormal plasma cells. Occupational exposure to certain chemicals and risky behaviors such as smoking and heavy alcohol consumption may also increase the risk of multiple myeloma in males. In addition, genetic mutations that increase the risk of multiple myeloma may also be more common in males.
Multiple myeloma is more prevalent in older adults, and since females generally have a longer lifespan than males, they are more susceptible to developing the disease. In addition, some research indicates that female hormones may contribute to developing multiple myeloma. For instance, estrogen may stimulate the proliferation of myeloma cells, elevating the risk of multiple myeloma in females.
United States has the highest Epidemiology Scenario Share
Based on the epidemiology scenario share, the report covers 10 top countries - United States, United Kingdom, Germany, France, Spain, Italy, Japan, Australia, China, and Australia.The United States' large and diverse population, advanced healthcare system, and robust research infrastructure have contributed to its dominance in the multiple myeloma industry. In addition, the country's favorable regulatory environment for new cancer treatments and numerous patient advocacy organizations have also played a role in the industry's growth.
The UK's robust healthcare system and strong tradition of medical research in multiple myeloma led to a high concentration of healthcare professionals and researchers with expertise in the country, along with a favorable regulatory environment for developing and approving new treatments. Additionally, several organizations' dedication in the UK raises awareness and supports patients and their families, leading to greater attention and funding for research in the field.
China's Increasing Number of Aging Population have increased the incidence of Multiple Myeloma
The United States, United Kingdom, Germany, France, Spain, Italy, Japan, Australia, China, and Saudi Arabia are the countries that comprise the multiple myeloma market in this report. China's growing and aging population has led to a higher incidence of multiple myeloma and growth in the industry. Increased healthcare spending due to economic development has improved cancer care, including for multiple myeloma. China's diverse patient population presents opportunities for new treatments and clinical trials, while government policies support the biopharmaceutical industry. Renowned research institutions and collaborations with international pharmaceutical companies have contributed to the transfer of advanced technologies and growth in the industry.
Renub Research report titled “Multiple Myeloma Market Global Forecast by Countries (United States, United Kingdom, Germany, France, Spain, Italy, Japan, Australia, China, and Saudi Arabia), Treatment Types (Targeted therapy, Chemotherapy, and Others), Epidemiology Scenario Share (United States, United Kingdom, Germany, France, Spain, Italy, Japan, Australia, China, and Australia), Gender share (Male, and Female)," provides a detailed analysis of Multiple Myeloma Market.
Countries - Market breakup from 10 Viewpoints:
1. United States
2. United Kingdom
3. Germany
4. France
5. Spain
6. Italy
7. Japan
8. Australia
9. China
10. Saudi Arabia
Treatment Types - Market breakup from 3 Viewpoints:
1. Targeted therapy
2. Chemotherapy
3. Others
Epidemiology Scenario Share - Market breakup from 10 Viewpoints:
1. United States
2. United Kingdom
3. Germany
4. France
5. Spain
6. Italy
7. Japan
8. Australia
9. China
10. Australia
Gender Share - Market breakup from 2 Viewpoints:
1. Male
2. Female
Report Details:
| Report Features | Details |
| Base Year | 2022 |
| Historical Period | 2018 - 2022 |
| Forecast Period | 2023 - 2030 |
| Market | US$ Billion |
| Segment Covered | Treatment Types, Gender, and Epidemiology |
| Countries Covered | United States, United Kingdom, Germany, France, Spain, Italy, Japan, Australia, China, and Saudi Arabia |
| Companies Covered | Sanofi , Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Bayer AG, Eli Lilly and Company, Merck & Co., Inc., and AstraZeneca |
| Customization Scope | 20% Free Customization |
| Post-Sale Analyst Support | 1 Year (52 Weeks) |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on request) |
1. Introduction
2. Research Methodology
3. Executive Summary
4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges
4.3 Opportunities
5. Porter’s Five Forces
5.1 Bargaining Power of Buyers
5.2 Bargaining Power of Suppliers
5.3 Degree of Competition
5.4 Threat of New Entrants
5.5 Threat of Substitutes
6 SWOT Analysis – Multiple Myeloma Market
6.1 Strengths
6.2 Weaknesses
6.3 Opportunities
6.4 Threats
7. Global Multiple Myeloma (MM) - Market & Patient Numbers
7.1 Multiple Myeloma Market
7.2 Multiple Myeloma Patient Population
8. Share Analysis - Global Multiple Myeloma
8.1 By Countries Market Share
8.2 By Treatment Types Market Share
8.3 By Epidemiology Scenario Share
8.4 By Gender Share
9. Multiple Myeloma - Disease Overview
9.1 Introduction
9.2 Symptoms and Diagnosis
9.3 Pathophysiology
9.4 Causes and Risk Factors
9.5 Treatment
10. Multiple Myeloma Patient Journey
11. Multiple Myeloma - Epidemiology and Patient Population
11.1 Epidemiology Scenario - Top 10 Markets
11.1.1 Epidemiology Scenario (2017-2022)
11.1.2 Epidemiology Forecast (2023-2030)
11.2 Epidemiology Scenario - United States
11.2.1 Epidemiology Scenario (2017-2022)
11.2.2 Epidemiology Forecast (2023-2030)
11.3 Epidemiology Scenario - Germany
11.3.1 Epidemiology Scenario (2017-2022)
11.3.2 Epidemiology Forecast (2023-2030)
11.4 Epidemiology Scenario - France
11.4.1 Epidemiology Scenario (2017-2022)
11.4.2 Epidemiology Forecast (2023-2030)
11.5 Epidemiology Scenario - United Kingdom
11.5.1 Epidemiology Scenario (2017-2022)
11.5.2 Epidemiology Forecast (2023-2030)
11.6 Epidemiology Scenario - Italy
11.6.1 Epidemiology Scenario (2017-2022)
11.6.2 Epidemiology Forecast (2023-2030)
11.7 Epidemiology Scenario - Spain
11.7.1 Epidemiology Scenario (2017-2022)
11.7.2 Epidemiology Forecast (2023-2030)
11.8 Epidemiology Scenario - Japan
11.8.1 Epidemiology Scenario (2017-2022)
11.8.2 Epidemiology Forecast (2023-2030)
11.9 Epidemiology Scenario - Australia
11.11.1 Epidemiology Scenario (2017-2022)
11.11.2 Epidemiology Forecast (2023-2030)
11.10 Epidemiology Scenario - China
11.10.1 Epidemiology Scenario (2017-2022)
11.10.2 Epidemiology Forecast (2023-2030)
11.11 Epidemiology Scenario - Saudi Arabia
11.11.1 Epidemiology Scenario (2017-2022)
11.11.2 Epidemiology Forecast (2023-2030)
12. Multiple Myeloma - Epidemiology and Patient Population - By Gender
12.1 Epidemiology Scenario - Top 10 Markets
12.1.1 Epidemiology Scenario Male and Forecast
12.1.2 Epidemiology Scenario Female Forecast
12.2 Epidemiology Scenario - United States
12.2.1 Epidemiology Scenario Male and Forecast
12.2.2 Epidemiology Scenario Female Forecast
12.3 Epidemiology Scenario - Germany
12.3.1 Epidemiology Scenario Male and Forecast
12.3.2 Epidemiology Scenario Female Forecast
12.4 Epidemiology Scenario - France
12.4.1 Epidemiology Scenario Male and Forecast
12.4.2 Epidemiology Scenario Female Forecast
12.5 Epidemiology Scenario - United Kingdom
12.5.1 Epidemiology Scenario Male and Forecast
12.5.2 Epidemiology Scenario Female Forecast
12.6 Epidemiology Scenario - Italy
12.6.1 Epidemiology Scenario Male and Forecast
12.6.2 Epidemiology Scenario Female Forecast
12.7 Epidemiology Scenario - Spain
12.7.1 Epidemiology Scenario Male and Forecast
12.7.2 Epidemiology Scenario Female Forecast
12.8 Epidemiology Scenario - Japan
12.8.1 Epidemiology Scenario Male and Forecast
12.8.2 Epidemiology Scenario Female Forecast
12.9 Epidemiology Scenario - Australia
12.9.1 Epidemiology Scenario Male and Forecast
12.9.2 Epidemiology Scenario Female Forecast
12.10 Epidemiology Scenario - China
12.12.1 Epidemiology Scenario Male and Forecast
12.12.2 Epidemiology Scenario Female Forecast
12.11 Epidemiology Scenario - Saudi Arabia
12.11.1 Epidemiology Scenario Male and Forecast
12.11.2 Epidemiology Scenario Female Forecast
13. Multiple Myeloma - Market Scenario
13.1 Market Scenario - Key Insights
13.2 Market Scenario - Top 10 Markets
13.2.1 Multiple Myeloma - Market Size (2017-2022)
13.2.2 Market Forecast (2023-2030)
13.3 Market Scenario - United States
13.3.1 Multiple Myeloma - Market Size (2017-2022)
13.3.2 Market Size Forecast (2023-2030)
13.3.3 Multiple Myeloma - Access and Reimbursement Overview
13.4 Market Scenario - Germany
13.4.1 Multiple Myeloma - Market Size (2017-2022)
13.4.2 Market Size Forecast (2023-2030)
13.4.3 Multiple Myeloma - Access and Reimbursement Overview
13.5 Market Scenario - France
13.5.1 Multiple Myeloma - Market Size (2017-2022)
13.5.2 Market Size Forecast (2023-2030)
13.5.3 Multiple Myeloma - Access and Reimbursement Overview
13.6 Market Scenario - United Kingdom
13.6.1 Multiple Myeloma - Market Size (2017-2022)
13.6.2 Market Size Forecast (2023-2030)
13.6.3 Multiple Myeloma - Access and Reimbursement Overview
13.7 Market Scenario - Italy
13.7.1 Multiple Myeloma - Market Size (2017-2022)
13.7.2 Market Size Forecast (2023-2030)
13.7.3 Multiple Myeloma - Access and Reimbursement Overview
13.8 Market Scenario - Spain
13.8.1 Multiple Myeloma - Market Size (2017-2022)
13.8.2 Market Size Forecast (2023-2030)
13.8.3 Multiple Myeloma - Access and Reimbursement Overview
13.9 Market Scenario - Japan
13.9.1 Multiple Myeloma - Market Size (2017-2022)
13.9.2 Market Size Forecast (2023-2030)
13.9.3 Multiple Myeloma - Access and Reimbursement Overview
13.10 Market Scenario - Australia
13.10.1 Multiple Myeloma - Market Size (2017-2022)
13.10.2 Market Size Forecast (2023-2030)
13.10.3 Multiple Myeloma - Access and Reimbursement Overview
13.11 Market Scenario - China
13.13.1 Multiple Myeloma - Market Size (2017-2022)
13.13.2 Market Size Forecast (2023-2030)
13.13.3 Multiple Myeloma - Access and Reimbursement Overview
13.12 Market Scenario - Saudi Arabia
13.12.1 Multiple Myeloma - Market Size (2017-2022)
13.12.2 Market Size Forecast (2023-2030)
13.12.3 Multiple Myeloma - Access and Reimbursement Overview
14. Multiple Myeloma - Treatment Algorithm, Guidelines, and Medical Practices
14.1 Guidelines, Management and Treatment
14.2 Treatment Algorithm
15. Multiple Myeloma Unmet Needs
16. Multiple Myeloma - Key Endpoints of Treatment
16.1 Targeted Therapy
16.2 Chemotherapy
16.3 Others
17. Multiple Myeloma - Marketed Products
17.1 List of Multiple Myeloma Marketed Drugs across the Top 10 Markets
17.1.1 Xpovio (Selinexor) - Karyopharm
17.1.1.1 Drug Overview
17.1.1.2 Mechanism of Action
17.1.1.3 Regulatory Status
17.1.1.4 Clinical Trial Results
17.1.1.5 Sales Across Major Markets
17.1.2 Velcade (Bortezomib) - Takeda Pharmaceutical/Janssen Pharmaceutical
17.1.2.1 Drug Overview
17.1.2.2 Mechanism of Action
17.1.2.3 Regulatory Status
17.1.2.4 Clinical Trial Results
17.1.2.5 Sales Across Major Markets
17.1.3 Proteasome inhibitor (Kyprolis)- Amgen / Ono (Japan)
17.1.3.1 Drug Overview
17.1.3.2 Mechanism of Action
17.1.3.3 Regulatory Status
17.1.3.4 Clinical Trial Results
17.1.3.5 Sales Across Major Markets
17.1.4 HDAC inhibitor (Farydak) - Novartis
17.1.4.1 Drug Overview
17.1.4.2 Mechanism of Action
17.1.4.3 Regulatory Status
17.1.4.4 Clinical Trial Results
17.1.4.5 Sales Across Major Markets
17.1.5 Sarclisa (Isatuximab) - Sanofi
17.1.5.1 Drug Overview
17.1.5.2 Mechanism of Action
17.1.5.3 Regulatory Status
17.1.5.4 Clinical Trial Results
17.1.5.5 Sales Across Major Markets
18. Multiple Myeloma - Pipeline Drugs
18.1 List of Multiple Myeloma Pipeline Drugs across the Top 10 Markets
18.1.1 Encorafenib - Array BioPharma/Ono Pharmaceutical/Pierre Fabre
18.1.1.1 Drug Overview
18.1.1.2 Mechanism of Action
18.1.1.3 Clinical Trial Results
18.1.1.4 Safety and Efficacy
18.1.1.5 Regulatory Status
18.1.2 Elranatamab - Pfizer
18.1.2.1 Drug Overview
18.1.2.2 Mechanism of Action
18.1.2.3 Clinical Trial Results
18.1.2.4 Safety and Efficacy
18.1.2.5 Regulatory Status
18.1.3 Alnuctamab - Celgene, Bristol-Myers Squibb
18.1.3.1 Drug Overview
18.1.3.2 Mechanism of Action
18.1.3.3 Clinical Trial Results
18.1.3.4 Safety and Efficacy
18.1.3.5 Regulatory Status
18.1.4 CAR-T ddBCMA - Gilead Sciences
18.1.4.1 Drug Overview
18.1.4.2 Mechanism of Action
18.1.4.3 Clinical Trial Results
18.1.4.4 Safety and Efficacy
18.1.4.5 Regulatory Status
18.1.5 Masitinib - AB Science
18.1.5.1 Drug Overview
18.1.5.2 Mechanism of Action
18.1.5.3 Clinical Trial Results
18.1.5.4 Safety and Efficacy
18.1.5.5 Regulatory Status
18.1.6 Nivolumab - Bristol-Myers Squibb/Ono Pharmaceuticals
18.1.6.1 Drug Overview
18.1.6.2 Mechanism of Action
18.1.6.3 Clinical Trial Results
18.1.6.4 Safety and Efficacy
18.1.6.5 Regulatory Status
19. Company Analysis
19.1 Sanofi (France)
19.1.1 Overview
19.1.2 Recent Developments
19.1.3 Financial Analysis
19.2 Pfizer Inc. (US)
19.2.1 Overview
19.2.2 Recent Developments
19.2.3 Financial Analysis
19.3 GlaxoSmithKline plc (UK)
19.3.1 Overview
19.3.2 Recent Developments
19.3.3 Financial Analysis
19.4 Novartis AG (Switzerland)
19.4.1 Overview
19.4.2 Recent Developments
19.4.3 Financial Analysis
19.5 Bayer AG (Germany)
19.5.1 Overview
19.5.2 Recent Developments
19.5.3 Financial Analysis
19.6 Eli Lilly and Company (US)
19.6.1 Overview
19.6.2 Recent Developments
19.6.3 Financial Analysis
19.7 Merck & Co., Inc. (US)
19.7.1 Overview
19.7.2 Recent Developments
19.7.3 Financial Analysis
19.8 AstraZeneca
19.8.1 Overview
19.8.2 Recent Developments
19.8.3 Financial Analysis
List of Figures:
Figure-01: Global – Multiple Myeloma (MM) Market (Billion US$), 2017 – 2022
Figure-02: Global – Forecast for Multiple Myeloma (MM) Market (Billion US$), 2023 – 2030
Figure-03: Global – Multiple Myeloma (MM) Patient Population (Thousand), 2017 – 2022
Figure-04: Global – Forecast for Multiple Myeloma (MM) Patient Population (THousand), 2023 – 2030
Figure-05: Top 10 Countries – Epidemiology Scenario Patient Population (Number), 2017 – 2022
Figure-06: Top 10 Countries – Forecast for Epidemiology Scenario Patient Population (Number), 2023 – 2030
Figure-07: United States – Epidemiology Scenario Patient Population (Number), 2017 – 2022
Figure-08: United States – Forecast for Epidemiology Scenario Patient Population (Number), 2023 – 2030
Figure-09: Germany – Epidemiology Scenario Patient Population (Number), 2017 – 2022
Figure-10: Germany – Forecast for Epidemiology Scenario Patient Population (Number), 2023 – 2030
Figure-11: France – Epidemiology Scenario Patient Population (Number), 2017 – 2022
Figure-12: France – Forecast for Epidemiology Scenario Patient Population (Number), 2023 – 2030
Figure-13: United Kingdom – Epidemiology Scenario Patient Population (Number), 2017 – 2022
Figure-14: United Kingdom – Forecast for Epidemiology Scenario Patient Population (Number), 2023 – 2030
Figure-15: Italy – Epidemiology Scenario Patient Population (Number), 2017 – 2022
Figure-16: Italy – Forecast for Epidemiology Scenario Patient Population (Number), 2023 – 2030
Figure-17: Spain – Epidemiology Scenario Patient Population (Number), 2017 – 2022
Figure-18: Spain – Forecast for Epidemiology Scenario Patient Population (Number), 2023 – 2030
Figure-19: Japan – Epidemiology Scenario Patient Population (Number), 2017 – 2022
Figure-20: Japan – Forecast for Epidemiology Scenario Patient Population (Number), 2023 – 2030
Figure-21: Australia – Epidemiology Scenario Patient Population (Number), 2017 – 2022
Figure-22: Australia – Forecast for Epidemiology Scenario Patient Population (Number), 2023 – 2030
Figure-23: China – Epidemiology Scenario Patient Population (Number), 2017 – 2022
Figure-24: China – Forecast for Epidemiology Scenario Patient Population (Number), 2023 – 2030
Figure-25: Saudi Arabia – Epidemiology Scenario Patient Population (Number), 2017 – 2022
Figure-26: Saudi Arabia – Forecast for Epidemiology Scenario Patient Population (Number), 2023 – 2030
Figure-27: Top 10 Countries – Epidemiology Scenario Male Patient Population (Number), 2017 – 2022
Figure-28: Top 10 Countries – Forecast for Epidemiology Scenario Male Patient Population (Number), 2023 – 2030
Figure-29: Top 10 Countries – Epidemiology Scenario Female Patient Population (Number), 2017 – 2022
Figure-30: Top 10 Countries – Forecast for Epidemiology Scenario Female Patient Population (Number), 2023 – 2030
Figure-31: United States – Epidemiology Scenario Male Patient Population (Number), 2017 – 2022
Figure-32: United States – Forecast for Epidemiology Scenario Male Patient Population (Number), 2023 – 2030
Figure-33: United States – Epidemiology Scenario Female Patient Population (Number), 2017 – 2022
Figure-34: United States – Forecast for Epidemiology Scenario Female Patient Population (Number), 2023 – 2030
Figure-35: Germany – Epidemiology Scenario Male Patient Population (Number), 2017 – 2022
Figure-36: Germany – Forecast for Epidemiology Scenario Male Patient Population (Number), 2023 – 2030
Figure-37: Germany – Epidemiology Scenario Female Patient Population (Number), 2017 – 2022
Figure-38: Germany – Forecast for Epidemiology Scenario Female Patient Population (Number), 2023 – 2030
Figure-39: France – Epidemiology Scenario Male Patient Population (Number), 2017 – 2022
Figure-40: France – Forecast for Epidemiology Scenario Male Patient Population (Number), 2023 – 2030
Figure-41: France – Epidemiology Scenario Female Patient Population (Number), 2017 – 2022
Figure-42: France – Forecast for Epidemiology Scenario Female Patient Population (Number), 2023 – 2030
Figure-43: United Kingdom – Epidemiology Scenario Male Patient Population (Number), 2017 – 2022
Figure-44: United Kingdom – Forecast for Epidemiology Scenario Male Patient Population (Number), 2023 – 2030
Figure-45: United Kingdom – Epidemiology Scenario Female Patient Population (Number), 2017 – 2022
Figure-46: United Kingdom – Forecast for Epidemiology Scenario Female Patient Population (Number), 2023 – 2030
Figure-47: Italy – Epidemiology Scenario Male Patient Population (Number), 2017 – 2022
Figure-48: Italy – Forecast for Epidemiology Scenario Male Patient Population (Number), 2023 – 2030
Figure-49: Italy – Epidemiology Scenario Female Patient Population (Number), 2017 – 2022
Figure-50: Italy – Forecast for Epidemiology Scenario Female Patient Population (Number), 2023 – 2030
Figure-51: Spain – Epidemiology Scenario Male Patient Population (Number), 2017 – 2022
Figure-52: Spain – Forecast for Epidemiology Scenario Male Patient Population (Number), 2023 – 2030
Figure-53: Spain – Epidemiology Scenario Female Patient Population (Number), 2017 – 2022
Figure-54: Spain – Forecast for Epidemiology Scenario Female Patient Population (Number), 2023 – 2030
Figure-55: Japan – Epidemiology Scenario Male Patient Population (Number), 2017 – 2022
Figure-56: Japan – Forecast for Epidemiology Scenario Male Patient Population (Number), 2023 – 2030
Figure-57: Japan – Epidemiology Scenario Female Patient Population (Number), 2017 – 2022
Figure-58: Japan – Forecast for Epidemiology Scenario Female Patient Population (Number), 2023 – 2030
Figure-59: Australia – Epidemiology Scenario Male Patient Population (Number), 2017 – 2022
Figure-60: Australia – Forecast for Epidemiology Scenario Male Patient Population (Number), 2023 – 2030
Figure-61: Australia – Epidemiology Scenario Female Patient Population (Number), 2017 – 2022
Figure-62: Australia – Forecast for Epidemiology Scenario Female Patient Population (Number), 2023 – 2030
Figure-63: China – Epidemiology Scenario Male Patient Population (Number), 2017 – 2022
Figure-64: China – Forecast for Epidemiology Scenario Male Patient Population (Number), 2023 – 2030
Figure-65: China – Epidemiology Scenario Female Patient Population (Number), 2017 – 2022
Figure-66: China – Forecast for Epidemiology Scenario Female Patient Population (Number), 2023 – 2030
Figure-67: Saudi Arabia – Epidemiology Scenario Male Patient Population (Number), 2017 – 2022
Figure-68: Saudi Arabia – Forecast for Epidemiology Scenario Male Patient Population (Number), 2023 – 2030
Figure-69: Saudi Arabia – Epidemiology Scenario Female Patient Population (Number), 2017 – 2022
Figure-70: Saudi Arabia – Forecast for Epidemiology Scenario Female Patient Population (Number), 2023 – 2030
Figure-71: Top 10 Countries – Multiple Myeloma (MM) Market (Million US$), 2017 – 2022
Figure-72: Top 10 Countries – Forecast for Multiple Myeloma (MM) Market (Million US$), 2023 – 2030
Figure-73: United States – Multiple Myeloma (MM) Market (Million US$), 2017 – 2022
Figure-74: United States – Forecast for Multiple Myeloma (MM) Market (Million US$), 2023 – 2030
Figure-75: Germany – Multiple Myeloma (MM) Market (Million US$), 2017 – 2022
Figure-76: Germany – Forecast for Multiple Myeloma (MM) Market (Million US$), 2023 – 2030
Figure-77: France – Multiple Myeloma (MM) Market (Million US$), 2017 – 2022
Figure-78: France – Forecast for Multiple Myeloma (MM) Market (Million US$), 2023 – 2030
Figure-79: United Kingdom – Multiple Myeloma (MM) Market (Million US$), 2017 – 2022
Figure-80: United Kingdom – Forecast for Multiple Myeloma (MM) Market (Million US$), 2023 – 2030
Figure-81: Italy – Multiple Myeloma (MM) Market (Million US$), 2017 – 2022
Figure-82: Italy – Forecast for Multiple Myeloma (MM) Market (Million US$), 2023 – 2030
Figure-83: Spain – Multiple Myeloma (MM) Market (Million US$), 2017 – 2022
Figure-84: Spain – Forecast for Multiple Myeloma (MM) Market (Million US$), 2023 – 2030
Figure-85: Japan – Multiple Myeloma (MM) Market (Million US$), 2017 – 2022
Figure-86: Japan – Forecast for Multiple Myeloma (MM) Market (Million US$), 2023 – 2030
Figure-87: Australia – Multiple Myeloma (MM) Market (Million US$), 2017 – 2022
Figure-88: Australia – Forecast for Multiple Myeloma (MM) Market (Million US$), 2023 – 2030
Figure-89: China – Multiple Myeloma (MM) Market (Million US$), 2017 – 2022
Figure-90: China – Forecast for Multiple Myeloma (MM) Market (Million US$), 2023 – 2030
Figure-91: Saudi Arabia – Multiple Myeloma (MM) Market (Million US$), 2017 – 2022
Figure-92: Saudi Arabia – Forecast for Multiple Myeloma (MM) Market (Million US$), 2023 – 2030
Figure-93: Targeted Therapy – Multiple Myeloma (MM) Market (Million US$), 2017 – 2022
Figure-94: Targeted Therapy – Forecast for Multiple Myeloma (MM) Market (Million US$), 2023 – 2030
Figure-95: Chemotherapy – Multiple Myeloma (MM) Market (Million US$), 2017 – 2022
Figure-96: Chemotherapy – Forecast for Multiple Myeloma (MM) Market (Million US$), 2023 – 2030
Figure-97: Others – Multiple Myeloma (MM) Market (Million US$), 2017 – 2022
Figure-98: Others – Forecast for Multiple Myeloma (MM) Market (Million US$), 2023 – 2030
Figure-99: Xpovio (Selinexor) - Karyopharm – Market (Million US$), 2018 – 2022
Figure-100: Xpovio (Selinexor) - Karyopharm – Forecast for Market (Million US$), 2023 – 2030
Figure-101: Velcade (Bortezomib) - Takeda Pharmaceutical/Janssen Pharmaceutical – Market (Million US$), 2018 – 2022
Figure-102: Velcade (Bortezomib) - Takeda Pharmaceutical/Janssen Pharmaceutical – Forecast for Market (Million US$), 2023 – 2030
Figure-103: Proteasome inhibitor (Kyprolis)- Amgen / Ono (Japan) – Market (Million US$), 2018 – 2022
Figure-104: Proteasome inhibitor (Kyprolis)- Amgen / Ono (Japan) – Forecast for Market (Million US$), 2023 – 2030
Figure-105: HDAC inhibitor (Farydak) - Novartis – Market (Million US$), 2018 – 2022
Figure-106: HDAC inhibitor (Farydak) - Novartis – Forecast for Market (Million US$), 2023 – 2030
Figure-107: Sarclisa (Isatuximab) - Sanofi – Market (Million US$), 2020 – 2022
Figure-108: Sarclisa (Isatuximab) - Sanofi – Forecast for Market (Million US$), 2023 – 2030
Figure-109: Sanofi – Global Revenue Market (Billion US$), 2018 – 2022
Figure-110: Sanofi – Forecast for Global Revenue Market (Billion US$), 2023 – 2030
Figure-111: Pfizer Inc. – Global Revenue Market (Billion US$), 2018 – 2022
Figure-112: Pfizer Inc. – Forecast for Global Revenue Market (Billion US$), 2023 – 2030
Figure-113: GlaxoSmithKline plc – Global Revenue Market (Billion US$), 2018 – 2022
Figure-114: GlaxoSmithKline plc – Forecast for Global Revenue Market (Billion US$), 2023 – 2030
Figure-115: Novartis AG – Global Revenue Market (Billion US$), 2018 – 2022
Figure-116: Novartis AG – Forecast for Global Revenue Market (Billion US$), 2023 – 2030
Figure-117: Bayer AG – Global Revenue Market (Billion US$), 2018 – 2022
Figure-118: Bayer AG – Forecast for Global Revenue Market (Billion US$), 2023 – 2030
Figure-119: Eli Lilly and Company – Global Revenue Market (Billion US$), 2018 – 2022
Figure-120: Eli Lilly and Company – Forecast for Global Revenue Market (Billion US$), 2023 – 2030
Figure-121: Merck & Co., Inc. – Global Revenue Market (Billion US$), 2018 – 2022
Figure-122: Merck & Co., Inc. – Forecast for Global Revenue Market (Billion US$), 2023 – 2030
Figure-123: AstraZeneca – Global Revenue Market (Billion US$), 2018 – 2022
Figure-124: AstraZeneca – Forecast for Global Revenue Market (Billion US$), 2023 – 2030
List of Tables:
Table-01: Global – Multiple Myeloma (MM) Market Share by Countries (Percent), 2018 – 2022
Table-02: Global – Forecast for Multiple Myeloma (MM) Market Share by Countries (Percent), 2023 – 2030
Table-03: Global – Multiple Myeloma (MM) Market Share by Treatment Type (Percent), 2018 – 2022
Table-04: Global – Forecast for Multiple Myeloma (MM) Market Share by Treatment Type (Percent), 2023 – 2030
Table-05: Global – Multiple Myeloma (MM) Volume Share by Epidemiology Scenario (Percent), 2018 – 2022
Table-06: Global – Forecast for Multiple Myeloma (MM) Volume Share by Epidemiology Scenario (Percent), 2023 – 2030
Table-07: Global – Multiple Myeloma (MM) Market Share by Gender (Percent), 2018 – 2022
Table-08: Global – Forecast for Multiple Myeloma (MM) Market Share by Gender (Percent), 2023 – 2030
Reach out to us
Call us on
USA: +1-678-302-0700
INDIA: +91-120-421-9822
Drop us an email at
info@renub.com